PUBLIC COMPANY
saveDAIICHI SANKYO
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
- phase1A Study of DS3610a in Participants With Advanced Solid Tumor
- phase2A Study of DS-3939a in Participants With Solid Tumors
- phase3Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- —Medical Access Program for DS-9606a (DS-9606) in Patients With Advanced Testicular Germ Cell Tumors
- phase1A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
- —A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
🐶 Hiring Signal
News
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.fiercebiotech · 16h ago
- FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classThe FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…fiercebiotech · 7d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 10d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 18d ago
- Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failureOno Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.biospace · 22d ago
- 8 companies hiring in New YorkLooking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month.biospace · 22d ago
- GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trialA phase 3 trial has linked GSK’s risvutatug rezetecan to a 67% reduction in the risk of disease progression or death, providing evidence that B7-H3-directed antibody-drug conjugates work in relapse…fiercebiotech · 24d ago
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.biopharma_dive · 25d ago
- BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD casesBioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to conclude its HER2-directed candidate may offer limited benefits in the…fiercebiotech · 25d ago
- ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP saysAt the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Al…biospace · 29d ago
comments(0)
5-min edit window · permanent after that